Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cesca Therapeutics has entered into a collaboration agreement with Center for Immune Cell Therapies (CICT) at Memorial Sloan Kettering Cancer Center focused on the CellWerks portfolio of devices for intra-laboratory stem cell purification applications.
Subscribe to our email newsletter
Under the terms of the agreement, CICT will utilize Cesca’s newest evolution of the AutoXpress® platform under the Company’s "Early Technology Access Program".
Specifically, this latest innovation of specialized cell processing algorithms will be applied to a CICT initiated study within the Adoptive Immune Cell Therapy Facility. The study’s completion is anticipated by the end of calendar year 2015.
Cesca Therapeutics senior vice president and chief biologist Mitchel Sivilotti said: "This agreement represents an important step forward for our hematology/oncology stem cell transplant program. This particular development initiative supports immuno-oncology, a field that has become a major focus of big pharma in the last year.
"The leading global pharmaceutical manufacturers have robust pipelines focused on isolating and using specialized cells to attack different types of cancers. The collaboration represents an example of Cesca’s drive to position its CellWerks device platform in this highly valued life-saving space."